Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib.

Jonathan Kay Masayoshi HarigaiJosh RancourtChristina DicksonThomas MelbyMaher IssaInmaculada de la Torre Yoshitaka IsakaAnabela CardosoChadi Saifan Edward C Keystone Ronald F Van Vollenhoven Jon T Giles Thomas Wj Huizinga Joel M Kremer

Published in: RMD open (2021)

Moderate decreases in neutrophils were seen during baricitinib treatment; however, serious infection was uncommon in patients with neutropenia. Transient increases were observed in lymphocytes and platelets, which returned to baseline over time. Changes in haemoglobin concentration were generally small. Haematological abnormalities seldom led to drug discontinuation.

Keyphrases

high intensity
peripheral blood
emergency department
adverse drug
red blood cell
blood brain barrier